Exome-chip meta-analysis identifies novel loci associated with cardiac conduction, including ADAMTS6

Bram P. Prins, St. George’s University of London
Timothy J. Mead, Cleveland Clinic
Jennifer A. Brody, University of Washington
Gardar Sveinbjornsson, deCODE Genet/Amgen, Inc.
Ioanna Ntalla, Queen Mary University of London
Nathan A. Bihlmeyer, Johns Hopkins University
Marteen van den Berg, Erasmus MC University Medical Center
Jette Bork-Jensen, University of Copenhagen
Stefania Cappellani, Institute for Maternal and Child Health
Stefan Van Duijvenboden, Queen Mary University of London

Only first 10 authors above; see publication for full author list.

Journal Title: Genome Biology
Volume: Volume 19, Number 1
Publisher: BMC (part of Springer Nature) | 2018-07-17, Pages 87-87
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1186/s13059-018-1457-6
Permanent URL: https://pid.emory.edu/ark:/25593/t5ncn

Final published version: http://dx.doi.org/10.1186/s13059-018-1457-6

Copyright information:
© The Author(s). 2018
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed March 20, 2019 2:08 AM EDT
Exome-chip meta-analysis identifies novel loci associated with cardiac conduction, including ADAMTS6


Abstract

Background: Genome-wide association studies conducted on QRS duration, an electrocardiographic measurement associated with heart failure and sudden cardiac death, have led to novel biological insights into cardiac function. However, the variants identified fall predominantly in non-coding regions and their underlying mechanisms remain unclear.

* Correspondence: yjamshid@sgul.ac.uk
† Bram P. Prins and Timothy J. Mead contributed equally to this work.
1 Genetics Research Centre, Molecular and Clinical Sciences Institute, St George’s University of London, London SW17 0RE, UK
20 Genetics Research Centre, Molecular and Clinical Sciences Institute, St George’s University of London, London, UK
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Full list of author information is available at the end of the article.
Background
In the heart, the ventricular conduction system propagates the electrical impulses that coordinate ventricular chamber contraction. The QRS interval on an electrocardiogram (ECG) is used clinically to quantify duration of ventricular depolarization in the heart. Prolonged QRS duration is an independent predictor of mortality in both the general population [1–4] and in patients with cardiac disease [5–10].

QRS interval duration is a quantitative trait influenced by multiple genetic and environmental factors and is known to be influenced by both age and gender [11, 12]. The heritability of QRS duration is estimated to be 35–55% from twin and family studies [13–16].

We previously performed a genome-wide association meta-analysis in 40,407 individuals and identified 22 genetic loci associated with QRS duration [17]. The QRS-associated loci highlighted novel biological processes such as kinase inhibitors, but also pointed to genes with established roles in ventricular conduction such as sodium channels, transcription factors, and calcium-handling proteins. However, the common risk variants identified in genome-wide association studies (GWAS) reside overwhelmingly in regulatory regions, making inference of the underlying causative genes difficult. Furthermore, as with most complex traits, the variants discovered to date explain only a small proportion of the total heritability (the “missing heritability” paradigm), suggesting additional variants are yet to be identified. In fact, the role of rare and low frequency variants, which cannot currently be detected using standard genome-wide single nucleotide polymorphism (SNP) chip arrays, have not been fully investigated. Here we used the Illumina HumanExome BeadChip to focus on rare (MAF < 1%), low frequency (MAF = 1–5%), and common (MAF ≥ 5%) putative functional coding variation associated with changes in ventricular depolarization.

Results and Discussion
We combined genotype data from 77,898 participants of European ancestry and 7695 of African descent participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Exome-Chip EKG consortium (Additional file 1: Table S1). A total of 228,164 polymorphic markers on the exome-chip array passed quality control and were used as a basis for our analyses. Through single variant analysis in the combined European and African datasets, we identified 34 variants across 28 loci associated with QRS duration that passed the exome-chip-wide significance threshold ($P < 6.17 \times 10^{-8}$ for single variants [Table 1, Additional file 2: Figure S1]). Eight of the identified loci were novel and five of these were driven by low frequency (MAF < 5%) and common (MAF ≥ 5%) non-synonymous coding variation. We confirmed 20 of the 29 previously identified QRS duration loci [14, 17–19], the remaining loci were not covered by the Exome-Chip and/or did not pass quality control (QC) (Additional file 1: Table S2). As might be anticipated when combining two ancestries in association analyses, we detected heterogeneity of effects for one variant (Cochran’s heterogeneity $P < 1.47 \times 10^{-3}$, a Bonferroni corrected $P$ value of $\alpha=0.05/34$ variants), Additional file 1: Table S2). We did not observe evidence for inflation of test statistics for any of the analyses ($\lambda_{GC} = 1.049$, European and African ancestries, combined, Additional file 2: Figure S2, individual ancestry results, Additional file 2: Figures S3–S6). We next sought to replicate the 34 lead variants of our 28 loci in a replication meta-analysis of 111,874 individuals from the UK Biobank [20] and deCODE genetics [21] cohorts. In the replication meta-analysis, 30 lead variants for 25 loci replicated ($P \leq 1.47 \times 10^{-3}$ = 0.05/34 variants), seven of which were novel, ten of which are known (Additional file 1: Table S2). The remaining four variants that did not replicate in UK Biobank encompass two previously established loci (one in locus SCN5A/SCN10A for which the other five variants replicated) and two novel
loci (SEN2P, IGF1R). This is likely due to differences in phenotype acquisition methods (UK Biobank having exercise ECGs measured), though effect size directions between discovery and replication remained consistent and \( P \) values of non-replicating variants were all below nominal significance (\( P < 0.05 \)).

**Sex-specific associations with QRS duration**

Sex differences in QRS duration are well established (men have significantly longer QRS durations than women [22, 23]), and might be attributable to differential effects of genetic variation in men and women. Therefore, we performed sex-stratified association analyses (Additional file 1: Table S3, Additional file 2: Figures S7 and S8). We included only those studies that had both male and female participants to mitigate potential bias due to contributions from single-sex cohorts. In total, up to 31,702 men and 39,907 women were included from both European and African ancestry studies. We found suggestive evidence for a sex-specific locus that was not identified in the combined analysis. The non-synonymous variant rs17265513 (p.As310Ser) in ZHX3 (zinc fingers and homeoboxes 3) showed a significant association only in men (\( P_{\text{male}} = 4.89 \times 10^{-8}, \beta(\text{SE}) = -0.52(0.09) \)), whereas no effect was observed for women (\( P_{\text{female}} = 0.86, \beta(\text{SE}) = -0.01(0.08) \)); however, there was no

---

**Table 1 Lead SNPs for 28 loci identified for QRS duration in a combined European and African American ancestry meta-analysis**

<table>
<thead>
<tr>
<th>Locus</th>
<th>Band</th>
<th>rsID</th>
<th>A1/A2</th>
<th>cMAF</th>
<th>beta(se)</th>
<th>( P )</th>
<th>n</th>
<th>Nearest gene</th>
<th>Annotation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Novel loci</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2q31.2</td>
<td>rs17362588</td>
<td>A/G</td>
<td>0.081</td>
<td>0.52 (0.08)</td>
<td>( 4.20 \times 10^{-11} )</td>
<td>85,593</td>
<td>CDCC14I</td>
<td>Non-synonymous</td>
</tr>
<tr>
<td>2</td>
<td>3p22.2</td>
<td>rs11620356</td>
<td>A/G</td>
<td>0.015</td>
<td>-1.63 (0.17)</td>
<td>( 1.23 \times 10^{-20} )</td>
<td>85,593</td>
<td>DELE1</td>
<td>Non-synonymous</td>
</tr>
<tr>
<td>3</td>
<td>3q27.2</td>
<td>rs6762208</td>
<td>A/C</td>
<td>0.357</td>
<td>-0.31 (0.05)</td>
<td>( 3.45 \times 10^{-12} )</td>
<td>85,593</td>
<td>SEN2P</td>
<td>Non-synonymous</td>
</tr>
<tr>
<td>4</td>
<td>6q22.32</td>
<td>rs4549631</td>
<td>C/T</td>
<td>0.481</td>
<td>0.28 (0.04)</td>
<td>( 5.56 \times 10^{-11} )</td>
<td>85,593</td>
<td>PRDL1</td>
<td>Intergenic</td>
</tr>
<tr>
<td>5</td>
<td>8q24.13</td>
<td>rs16896961</td>
<td>G/C</td>
<td>0.040</td>
<td>-0.02 (0.11)</td>
<td>( 7.51 \times 10^{-16} )</td>
<td>79,976</td>
<td>KCHK38</td>
<td>Non-synonymous</td>
</tr>
<tr>
<td>6</td>
<td>12q13.3</td>
<td>rs2926743</td>
<td>A/G</td>
<td>0.257</td>
<td>-0.32 (0.05)</td>
<td>( 9.40 \times 10^{-11} )</td>
<td>85,593</td>
<td>NACA</td>
<td>Non-synonymous</td>
</tr>
<tr>
<td>7</td>
<td>15q26.3</td>
<td>rs4966020</td>
<td>G/A</td>
<td>0.387</td>
<td>-0.27 (0.04)</td>
<td>( 2.99 \times 10^{-9} )</td>
<td>85,593</td>
<td>IGF1R</td>
<td>Intergenic</td>
</tr>
<tr>
<td>8</td>
<td>20p12.3</td>
<td>rs961253</td>
<td>A/C</td>
<td>0.357</td>
<td>0.30 (0.04)</td>
<td>( 1.20 \times 10^{-11} )</td>
<td>85,593</td>
<td>CASC20</td>
<td>Intergenic</td>
</tr>
<tr>
<td><strong>Previously identified loci</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>1p32.3</td>
<td>rs11588271</td>
<td>A/G</td>
<td>0.333</td>
<td>-0.34 (0.05)</td>
<td>( 7.59 \times 10^{-14} )</td>
<td>85,593</td>
<td>CDKN2C</td>
<td>Intergenic</td>
</tr>
<tr>
<td>10</td>
<td>1p31.1</td>
<td>rs4074536</td>
<td>C/T</td>
<td>0.305</td>
<td>-0.20 (0.08)</td>
<td>( 8.27 \times 10^{-10} )</td>
<td>85,593</td>
<td>CASQ2</td>
<td>Non-synonymous</td>
</tr>
<tr>
<td>11</td>
<td>2p22.2</td>
<td>rs7562790</td>
<td>G/T</td>
<td>0.424</td>
<td>0.37 (0.04)</td>
<td>( 4.34 \times 10^{-17} )</td>
<td>85,593</td>
<td>CRIM1</td>
<td>Intergenic</td>
</tr>
<tr>
<td>12</td>
<td>2p22.2</td>
<td>rs17020136</td>
<td>C/T</td>
<td>0.185</td>
<td>0.38 (0.07)</td>
<td>( 1.02 \times 10^{-8} )</td>
<td>59,876</td>
<td>HEATR5B</td>
<td>Intergenic</td>
</tr>
<tr>
<td>13</td>
<td>3p22.2</td>
<td>rs6795970</td>
<td>A/G</td>
<td>0.371</td>
<td>0.80 (0.05)</td>
<td>( 9.19 \times 10^{-70} )</td>
<td>85,593</td>
<td>SCN10A</td>
<td>Non-synonymous</td>
</tr>
<tr>
<td>14</td>
<td>3p21.1</td>
<td>rs4687718</td>
<td>A/G</td>
<td>0.164</td>
<td>-0.36 (0.06)</td>
<td>( 1.19 \times 10^{-46} )</td>
<td>83,134</td>
<td>TKT</td>
<td>Intergenic</td>
</tr>
<tr>
<td>15</td>
<td>5q33.2</td>
<td>rs13165478</td>
<td>A/G</td>
<td>0.377</td>
<td>-0.68 (0.04)</td>
<td>( 6.74 \times 10^{-52} )</td>
<td>85,593</td>
<td>HAND1</td>
<td>Intergenic</td>
</tr>
<tr>
<td>16</td>
<td>6p21.2</td>
<td>rs9470361</td>
<td>A/G</td>
<td>0.249</td>
<td>0.84 (0.05)</td>
<td>( 1.21 \times 10^{-63} )</td>
<td>85,593</td>
<td>CDKN1A</td>
<td>Intergenic</td>
</tr>
<tr>
<td>17</td>
<td>6q22.31</td>
<td>rs11153730</td>
<td>C/T</td>
<td>0.475</td>
<td>0.56 (0.04)</td>
<td>( 1.99 \times 10^{-38} )</td>
<td>85,593</td>
<td>SLC35F1</td>
<td>Intergenic</td>
</tr>
<tr>
<td>18</td>
<td>7p14.2</td>
<td>rs1362212</td>
<td>A/G</td>
<td>0.144</td>
<td>0.55 (0.06)</td>
<td>( 1.22 \times 10^{-18} )</td>
<td>85,593</td>
<td>TBX20</td>
<td>Intergenic</td>
</tr>
<tr>
<td>19</td>
<td>7p12.3</td>
<td>rs7784776</td>
<td>G/A</td>
<td>0.397</td>
<td>0.27 (0.04)</td>
<td>( 1.18 \times 10^{-9} )</td>
<td>85,593</td>
<td>IGFBP3</td>
<td>Intergenic</td>
</tr>
<tr>
<td>20</td>
<td>7q31.2</td>
<td>rs3807989</td>
<td>A/G</td>
<td>0.427</td>
<td>0.40 (0.04)</td>
<td>( 2.14 \times 10^{-10} )</td>
<td>85,593</td>
<td>CAV1</td>
<td>Intergenic</td>
</tr>
<tr>
<td>21</td>
<td>12q42.1</td>
<td>rs3825214</td>
<td>G/A</td>
<td>0.200</td>
<td>0.46 (0.05)</td>
<td>( 1.10 \times 10^{-17} )</td>
<td>85,593</td>
<td>TBX5</td>
<td>Intergenic</td>
</tr>
<tr>
<td>22</td>
<td>12q42.1</td>
<td>rs7966651</td>
<td>T/C</td>
<td>0.270</td>
<td>-0.38 (0.05)</td>
<td>( 6.74 \times 10^{-15} )</td>
<td>85,593</td>
<td>TBX3</td>
<td>Intergenic</td>
</tr>
<tr>
<td>23</td>
<td>13q22.1</td>
<td>rs1886512</td>
<td>A/T</td>
<td>0.380</td>
<td>-0.36 (0.05)</td>
<td>( 3.17 \times 10^{-13} )</td>
<td>70,887</td>
<td>KLF12</td>
<td>Intergenic</td>
</tr>
<tr>
<td>24</td>
<td>14q24.2</td>
<td>rs11848785</td>
<td>G/A</td>
<td>0.237</td>
<td>-0.44 (0.05)</td>
<td>( 5.59 \times 10^{-18} )</td>
<td>85,593</td>
<td>SPC4L1</td>
<td>Intergenic</td>
</tr>
<tr>
<td>25</td>
<td>17q21.32</td>
<td>rs17608766</td>
<td>C/T</td>
<td>0.127</td>
<td>0.70 (0.07)</td>
<td>( 9.81 \times 10^{-27} )</td>
<td>85,593</td>
<td>GOSR2</td>
<td>UTR</td>
</tr>
<tr>
<td>26</td>
<td>17q24.2</td>
<td>rs9914268</td>
<td>G/C</td>
<td>0.416</td>
<td>0.43 (0.05)</td>
<td>( 2.34 \times 10^{-21} )</td>
<td>79,976</td>
<td>PRKCA</td>
<td>Intergenic</td>
</tr>
<tr>
<td>27</td>
<td>18q12.3</td>
<td>rs663651</td>
<td>G/A</td>
<td>0.446</td>
<td>-0.44 (0.05)</td>
<td>( 6.59 \times 10^{-18} )</td>
<td>61,604</td>
<td>SETBP1</td>
<td>Non-synonymous</td>
</tr>
<tr>
<td>28</td>
<td>20q12.2</td>
<td>rs3746435</td>
<td>C/G</td>
<td>0.190</td>
<td>-0.36 (0.06)</td>
<td>( 2.67 \times 10^{-10} )</td>
<td>79,976</td>
<td>MIY7B</td>
<td>Non-synonymous</td>
</tr>
</tbody>
</table>

Top panel: novel loci; bottom panel: previously identified loci

Locus index number for each independent locus, Band cytogenetic band in which the lead SNP for the locus resides, dbSNPID dbSNP rs-number of the lead SNP of the locus, A1/A2 censed/censored alleles, cMAF cumulative minor allele frequency, beta(se) effect size (standard error) in ms, \( P \) value, n total number of individuals analyzed for this variant, Nearest gene (nearest) gene, Annotation variant function (protein coding)
significant difference consistent with an interaction with sex ($P = 2.3 \times 10^{-5}$). Additionally, no further evidence was observed in the replication analyses alone ($P_{\text{male}} = 7.95 \times 10^{-3}$, $\beta(\text{SE}) = -0.30(0.09)$, $N_{\text{males}} = 50,457$), ($P_{\text{female}} = 3.55 \times 10^{-2}$, $\beta(\text{SE}) = -0.17(0.08)$, $N_{\text{females}} = 61,417$).

**Association of coding and non-coding variants with QRS duration**

Among the eight newly identified loci in the sex-combined analysis, five had lead variants that were non-synonymous: *CCDC141* (Coiled-Coil Domain Containing 141); *KLHL38* (Kelch Like Family Member 38); *DLEC1* (Deleted in Lung and Esophageal Cancer 1); *NACA* (Nascent Polypeptide-Associated Complex Alpha subunit); and *SENP2* (SUMO1/Sentrin/SMT3 Specific Protease 2). Suggestive evidence for association of the same non-synonymous variant in *CCDC141* (rs17362588; $P = 4.75 \times 10^{-7}$) and an intronic variant in *KLHL38* (rs11991744; $P = 1.25 \times 10^{-7}$) with QRS duration was shown in two earlier GWAS [24, 25]. *DLEC1* has recently been suggested to have a possible role as a tumor suppressor [26], and while specific roles for *KLHL38* and *CCDC141* (a centrosome associated protein) have not yet been elucidated, they show the highest expression in skeletal and/or cardiac tissue, respectively, among the tissues examined in the Genotype-Tissue Expression (GTEX) Portal database (http://www.gtexportal.org) [27]. Two of the novel loci, *NACA* and *SENP2*, have established roles in cardiac development and dysfunction. *NACA* produces the isoform skNAC (skeletal NACA) and acts as a skeletal muscle- and heart-specific transcription factor and is critical for ventricular cardiomyocyte expansion [28]. Cardiac-specific knockdown of skNAC in a *Drosophila* Hand4.2-Gal4 driver cell-line results in severe cardiac defects [19]. Cardiac-specific overexpression of *SENP2*, a SUMO-specific protease, leads to congenital heart defects and cardiac dysfunction [29].

In the sex-stratified analysis, the association with *ZHX3* (Zinc Fingers and Homeoboxes 3) was also driven by an amino acid changing variant. *ZHX3* encodes a transcriptional repressor whose functions are largely unknown. However, the sex-specific association might be explained by hormonal changes that have previously been hypothesized to explain a variety of sex-specific differences observed in ECG measures and conduction disorders [30, 31]. A sex-specific association of *ZHX3* has also been previously shown for total cholesterol levels (the effect is only significant in men) [32].

We further identified an intrinsic variant in the *IGF1R* (Insulin Like Growth Factor 1 Receptor) locus and two intergenic variants: rs4549631 at locus 6q22.32 and rs961253 at locus 20p12.3. Interestingly, when queried against results from the GTEx project portal [27] for blood and eight tissues (including adipose [subcutaneous], artery [aorta, coronary, tibial], heart [atrium, appendage, left ventricle], lung, muscle [skeletal], nerve [tibial], skin [sun exposed], and thyroid), the lead intronic variant in *IGF1R* (rs4966020; MAF EA/AA 0.36/0.63) is a left ventricle tissue-specific cis-eQTL ($P = 2.4 \times 10^{-7}$). The variant is also in strong linkage disequilibrium with the strongest cis-eQTL for this tissue (rs4966021, $P = 5 \times 10^{-8}$). *IGF1R* promotes physiological hypertrophy but protects against cardiac fibrosis [33]; the signaling pathways induced by its binding partner, IGF1, regulate contractility, metabolism, hypertrophy, autophagy, senescence, and apoptosis in the heart [34]. The nearest genes for the two intergenic variants are *PRELID1P1* (*PRELI Domain Containing 1 Pseudogene* 1 [locus 6q22.32]) and *CASC20* (Cancer Susceptibility Candidate 20 [non-protein-coding]; locus 20p12.3)—the former a pseudogene and the latter a non-protein-coding gene, both with currently uncharacterized function.

**Rare ADAMTS6 variants are associated with QRS duration**

By collapsing rare variant in genes as functional units and jointly testing these for association, substantial statistical power-gains can be achieved [35]. We, therefore, performed gene-based analyses using both the Sequence Kernel Association Test (SKAT) (Additional file 1: Table S4) and burden test (T1) (Additional file 1: Table S5), because these tests have optimal power under different scenarios. Analyses were restricted to variants with MAF < 1% in a total of 16,085 genes. One gene-based significant association ($P < 5.18 \times 10^{-7}$) was identified in *ADAMTS6* (A Disintegrin-Like And Metalloproteinase with Thrombospondin Type 1 Motif 6; $P_{\text{SKAT}} = 8.18 \times 10^{-8}$, Table 2), when including only variants classified as damaging (see “Methods”). Four additional genes showed suggestive evidence of association ($P < 1 \times 10^{-5}$) (Table 2).

The *ADAMTS6* gene-based signal is driven by two rare non-synonymous variants: rs61736454 (p.Ser90Leu) and rs114007286 (p.Arg603Trp), which have allele frequencies of 0.0018 and 0.0021, respectively (Additional file 1: Table S6). Notably, a look-up in the independent deCODE QRS duration analysis showed that rs61736454 was highly significant, however not exome-wide ($P = 2.65 \times 10^{-7}$, $\beta(\text{SE}) = 3.01(0.58)$), MAF = 0.002, $N = 59,903$, and was extremely well imputed (info score = 0.995). Importantly, after meta-analysis with discovery exome summary statistics, the signal reached exome-wide significance ($P = 8.96 \times 10^{-13}$, $\beta(\text{SE}) = 2.75(0.38)$), $N = 145,496$, underscoring the robustness of our initial discovery signal driver. Data for rs114007286 were not available. *ADAMTS6* is a highly constrained gene, with a probability of loss of function intolerance score of 1.0 (pLI = 1.0) (Exome Aggregation Consortium [ExAC, Cambridge, MA, USA; http://exac.broadinstitute.org/]). The p.Ser90Leu variant lies within the ADAMTS6 propeptide, which is predicted to be important for
initiation of folding, because the homologous ADAMTS9 propeptide is an intramolecular chaperone essential for its secretion [36]. The second variant, p.Arg603Trp, is located in the N-terminal-most TSR domain (TSR1) of ADAMTS6. This domain is the target of protein-O-fucosylation, which is a QC signal that prevents secretion of ADAMTS proteins that are improperly folded [37].

**ADAMTS6 is necessary for cardiac development and expression of gap junction protein Cx43**

ADAMTS6 belongs to a family of metalloproteases that mediates extracellular proteolytic processing of extracellular matrix (ECM) components and other secreted molecules. ADAMTS6 is closely related to ADAMTS10, which interacts with and accelerates assembly of fibrillin-1, mutations in which cause Marfan syndrome [38]. This suggests that ADAMTS6 could regulate cardiac ECM. While no specific ADAMTS6 substrates have been unequivocally identified, it was reported to regulate focal adhesions, epithelial cell–cell interactions, and microfilibril assembly in cultured cells [39]. We show by RNA in situ hybridization that 

**Table 2** Gene-based test association results (for genes with variants classified as damaging)

<table>
<thead>
<tr>
<th>Gene</th>
<th>N_{SNP}</th>
<th>cMAF</th>
<th>beta(se)_{T1-Burden}</th>
<th>Pt1-Burden</th>
<th>PSKAT</th>
<th>Protein function</th>
<th>Cardiac-specific involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAMTS6</td>
<td>12</td>
<td>0.0097</td>
<td>−0.72 (0.23)</td>
<td>1.48 × 10^{-3}</td>
<td>8.18 × 10^{-8}</td>
<td>Zinc-dependent protease</td>
<td>–</td>
</tr>
<tr>
<td>CSRP3</td>
<td>3</td>
<td>0.0048</td>
<td>1.38 (0.31)</td>
<td>9.65 × 10^{-6}</td>
<td>9.10 × 10^{-6}</td>
<td>Regulator of myogenesis</td>
<td>Myocyte cytoarchitecture maintenance</td>
</tr>
<tr>
<td>FHOD3</td>
<td>17</td>
<td>0.0171</td>
<td>0.00 (0.17)</td>
<td>9.86 × 10^{-1}</td>
<td>1.82 × 10^{-5}</td>
<td>Actin filament assembly</td>
<td>Myofibril development and repair</td>
</tr>
<tr>
<td>ISM1</td>
<td>5</td>
<td>0.0137</td>
<td>0.17 (0.36)</td>
<td>5.05 × 10^{-5}</td>
<td>5.88 × 10^{-5}</td>
<td>Angiogenesis inhibitor</td>
<td>–</td>
</tr>
<tr>
<td>TBX5</td>
<td>8</td>
<td>0.0171</td>
<td>−0.52 (0.17)</td>
<td>5.21 × 10^{-2}</td>
<td>7.80 × 10^{-5}</td>
<td>T-box transcription factor</td>
<td>Cardiac development and cell cycle control</td>
</tr>
</tbody>
</table>

Displayed are the top five genes that have the lowest P values in the SKAT test (for genes with damaging variants)

Genes in which variants were collapsed, N_{SNP}, number of variants used in the collapsed variant test, cMAF cumulative minor allele frequency of variants in the test, beta(se)_{T1-Burden} effect size (standard error) in ms, Pt1-Burden P value of T1-burden test, PSKAT P value of SKAT test, Protein function function of the protein encoded by respective gene, Cardiac-specific involvement, literature support for physiological involvement of the protein in the heart

ADAMTS6 mutants show Cx43 is completely absent in the ventricular myocardium (Fig. 2a and b). Thus, whereas 

**Rare ADAMTS6 coding variants lead to impaired ADAMTS6 secretion**

To determine the functional consequences of the two predicted pathogenic human ADAMTS6 coding variants from the exome-chip analysis (p.Ser90Leu and p.Arg603Trp), myc-tagged ADAMTS6 constructs with the variants introduced by site-directed mutagenesis were expressed in HEK293F cells. Western blotting was used to compare the levels of mutant and wild type (WT) myc-tagged ADAMTS6 in the transfected cell lysates and medium. As positive and negative controls, respectively, we transfected the known pathogenic murine variant (p.Ser149Arg) and two rare non-synonymous human ADAMTS6 variants predicted to be benign (p.Ser210Leu and p.Met752Val). Western blotting confirmed that the ADAMTS6 p.Ser149Arg variant was not secreted (Fig. 3a). The predicted human pathogenic variants show much reduced secretion compared to the WT and benign variants (Fig. 3b–d).
Significantly, the molecular masses of the secreted p.Ser90-Leu and p.Arg603Trp variants observed in cell lysate are comparable to that of the WT protein, indicating normal glycosylation and propeptide excision, which are essential for ADAMTS zymogen conversion to their mature forms [44]. These results suggest that heterozygous individuals have a reduction of secreted ADAMTS6 to 50% of normal, implying reduced proteolytic activity. The resulting disruption of proteolytic remodeling could potentially affect cell–cell and cell–matrix interactions essential for efficient Cx43 gap junction assembly. However, the rs61736454 (p.Ser90-Leu) and rs114007286 (p.Arg603Trp) variants were associated with longer and shorter QRS duration, respectively. The reduced secretion observed was more profound for the rs61736454 variant compared to rs114007286, and the assay does not predict what impact a small amount of secreted protein may have, nor how it interacts in the presence of other modifier genes/variants carried by the same individual. Additionally, the two variants might affect overall protein function and interaction with binding partners in different ways.

**Conclusions**

In a meta-analysis of data from 77,898 participants of European ancestry and 7695 of African descent in our discovery cohort participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Exome-Chip ECG consortium, we identified 28 loci associated with QRS duration. With the addition of 111,874 individuals of European ancestry from the UK Biobank and deCODE cohorts, all 34 variants across the 28 loci passed the exome-chip-wide significance threshold, indicating our results are robust. Furthermore, effect size directions between discovery and replication remained consistent and P values of non-replicating variants in the replication analysis alone were all below nominal significance (P < 0.05). Novel loci include genes involved in cardiac development and dysfunction, some of which are highly expressed in...
skeletal and/or cardiac tissue. To establish further evidence for these novel loci and mechanisms underlying each association, future functional experiments are essential.

The present study also highlights the efficacy of large-scale population-based exome-chip analysis for discovery of non-synonymous coding variants with significant functional effects. In gene-based tests, we identified an association between ventricular depolarization and rare non-synonymous variants in ADAMTS6, a gene not previously implicated in cardiac conduction. We chose to focus on this novel locus and seek functional validation as the association was driven by multiple rare coding variants that were predicted to be damaging by in silico tools. The coding variants driving the association in the population study and the mutations identified in the mouse forward genetic screen all impair ADAMTS6 secretion, indicating reduction/loss of function. Significantly, although heterozygosity of the variants in mice is not associated with structural heart defects, we detected reduction of Cx43 gap junctions in the ventricular myocardium. Homozygous Adamts6 mutants show complete loss of Cx43 gap junctions as well as structural heart defects, implying a dosage effect. Together, these findings indicate that ADAMTS6 has a novel role in regulating gap junction-mediated ventricular depolarization, with quantitative reduction in ADAMTS6 causing cardiac conduction perturbation. While our study focuses on cardiac conduction, the findings support the potential broad utility of large-scale exome-chip analysis for interrogating coding variants associated with other physiological or clinical parameters.

Methods

Discovery association analyses

Study cohorts

All participating studies formed the CHARGE EKG exome-chip consortium, including those belonging to the CHARGE consortium and external studies to investigate the role of functional variation in electrocardiographic traits. Twenty-two cohorts participated in the QRS duration analysis effort representing a maximum total sample size of 85,593 samples, consisting of 77,898 participants of European ancestry (91%) and 7695 of African descent. Individual study details and characteristics are summarized in Additional file 1: Table S1.
Phenotype measurements

We analyzed QRS duration measured in milliseconds. In each study, individuals were excluded from the analyses if these had a QRS duration of > 120 ms, atrial fibrillation (AF) on baseline electrocardiogram, a history of myocardial infarction or heart failure, had Wolff–Parkinson–White syndrome (WPW), a pacemaker, or used Class I and class III blocking medications (those medications with prefix C01B* according to the Anatomical Therapeutic Chemical (ATC) Classification System, http://www.whocc.no/atcddd/) [45]. For cohorts that were disease case-control studies, we included only the control subjects in our analyses irrespective of the nature of the case disease.

Genotyping and quality control

Each participating study performed genotyping using the Illumina HumanExome BeadChip / HumanCoreExome platforms. Owing to the difficulty of accurately detecting and assign genotype calls for rare variants (MAF < 1%), an initial core set of CHARGE cohorts, comprising approximately 62,000 samples, assembled intensity data into a single project for a joint improved calling. The quality of the joint calling was assessed through investigating the concordance of genotypes in samples having both exome-chip and exome-sequence data, described extensively elsewhere [46, 47]. Using the curated clustering files from the CHARGE central calling effort, several cohorts within our study re-called their genotypes. The remainder of participating studies used either Gencall [48] or zCall [49], or a combination of both. Full details concerning the genotyping and quality control for each cohort are summarized in Additional file 1: Table S1. Individual studies performed sample-level genotype QC filtering for call rate, removing autosomal heterozygosity outliers, gender mismatches, duplicates as established by identity by descent (IBD) analysis, and removed ethnic outliers as determined by multidimensional scaling. Poorly called variants were typically removed by filtering for Hardy-Weinberg equilibrium test P value (pHWE), call rate, and filtering removing poorly clustering variants. Each study aligned their data reference strand to the Illumina forward strand using a central SNP allele reference and annotation file (SNP info file) [46] for the Illumina Exome Chip. Variants were all mapped to GRCh37/hg19. Only variants present within the SNP info file were initially considered for analyses, 247,871 in total. Next, we filtered out 9252 variants that
failed QC in the joint calling effort, as well as 6591 variants with inconsistent reference alleles across studies (a total of 11,392 unique SNPs), and considered furthermore only autosomal and chromosome X variants, and only those that were polymorphic in our study, leaving an initial set of 228,164 variants for analysis. For our single variant analyses, we only included variants with MAF > 0.012% (equal to a minor allele count [MAC] of 10), 162,199 in total.

Statistical methods

All association analyses were carried out using the R-package seqMeta [50]. Each study ran the “prepScores” function and adjusted their analyses for age, gender, body mass index (BMI), height, principal components, and study-specific covariates when appropriate (details in Additional file 1: Table S1). The output of this function is an R “list” object (“prepScores object”), stored in an .RData file, where each element corresponds to a gene, and contains the scores and MAFs for variants, as well as a matrix of the covariance between the scores at all pairs of SNPs within a gene. All studies performed both gender combined and separated analyses, in addition to separation by ancestry. Using the prepScores objects from each study, we performed meta-analyses using the “singlesnpMeta()” for single variant meta-analyses, and the “burdenMeta” and “skatMeta()” functions of SeqMeta. Coefficients and standard errors from seqMeta can be interpreted as a “one-step” approximation to the maximum likelihood estimates. Ancestry groups were analyzed both separate and combined at the meta-analysis level.

For single variant meta-analyses, we included all variants with a MAC ≥ 10 in order to have well-calibrated type I error rates [51]. Statistical significance was defined using Bonferroni corrections. For single variants, maximally 162,199 variants were included in five separate analyses after filtering for MAC: European and African ancestry separated and combined (n = 3); and sex-stratified analyses (n = 2), resulting in a Bonferroni corrected P value of α=0.05 / 162,199 variants / 5 analyses = 6.17 × 10^{-8}.

Suggestive sex dimorphic associations were identified by performing sex-stratified meta-analyses, totaling 39,907 women and 31,702 men, including only from cohorts that had both male and female samples. Variants were deemed to be suggestive sex-specific when reaching below a P value threshold of exome-wide significance (P < 6.17 × 10^{-8}) in one sex and above nominal significance in the other (P > 0.05).

For gene-based tests, also performed using seqMeta using the “prepScores” objects from individual cohorts, we assigned variants to genes by annotating all variants on the Exome Chip using ANNOVAR [52] following RefSeq [53] gene definitions mapped to human genome build 37 (hg19). In the collapsed variant tests, we included only variants with MAF < 1% and included only genes for which two or more variants were present (n = 16,085). We performed both SKAT [54] and T1 burden [55] tests, for three different functional sets of variants limited to the following: (I) all variants; (II) missense, nonsense, splice, and indel variants; (III) “damaging”: the same variants as in group II, except for missense only including those that are predicted to be damaging by at least two out of four functional prediction algorithms (Polyphen2 [56], SIFT [57], Mutation Taster [58], and LRT [59]). For the gene-based tests, we used a Bonferroni corrected P value significance threshold of α=0.05 / 16,085 genes / 2 different tests / 3 functional variant classes = 5.18 × 10^{-7}.

We define a physically independent locus as the genomic region that contains variants within 250 kb on either side of LD-independent lead SNPs (exome-wide significant variants with r² < 0.1), where LD calculations were based on European ancestry. Following this definition, in certain cases LD-independent lead variants are present in overlapping regions, complicating the definition and reporting of associated genetic loci and harbored genes. Therefore, we annealed loci if LD-independent exome-wide significant variants were < 250 kb from each other. Where lead SNPs from previous analyses were not contained in these regions, we considered these as novel. LD calculations were performed on the Illumina Exome Chip genotype data from the TwinsUK cohort [60] (n = 1194), using PLINK 1.9 [61].
between the onset of the Q wave and the end of the S wave. Genotyping was performed by UKB using the Applied Biosystems UK BiLEVE Axiom Array or the UKB AxiomTM Array. Single Nucleotide Variants (SNVs) were imputed centrally by UKB using a merged UK10K sequencing + 1000 Genomes imputation reference panel (https://www.biorxiv.org/content/early/2017/07/20/166298).

Following phenotype and genotype QC, a total of 51,971 unrelated individuals of European ancestry remained for analysis. Thirty-four QRS discovery lead variants selected for replication were extracted from UKB imputed files, all being of high quality (Hardy-Weinberg $P > 1 \times 10^{-4}$ and an info score > 0.5) using QCTOOL v2 and the association analysis was performed using SNPTEST v2.5.4 assuming an additive genetic model.

Study cohort: deCODE

ECGs obtained in Landspitali—The National University Hospital of Iceland, Reykjavik, the largest and only tertiary care hospital in Iceland—have been digitally stored since 1998. For this analysis, we used information on mean QRS duration in milliseconds from 151,667 sinus rhythm ECGs from 59,903 individuals. Individuals with permanent pacemakers or history of myocardial infarction, heart failure, atrial fibrillation, or WPW were excluded, as well as ECGs with QRS duration > 120 ms. ECG measurements were adjusted for sex, year of birth, and age at measurement. Due to limited availability of information, height, BMI, or drugs were not accounted for in the analysis. The genotypes in the deCODE study were derived from whole-genome sequencing of 28,075 Icelanders using Illumina standard TruSeq methodology to a mean depth of 35X (SD 8X) with subsequent imputation into 160,000 chip-typed individuals and their close relatives [21]. Selected replication variants from the meta-analysis for association with QRS duration were tested in accounting for relatedness using a mixed effects model as implemented by BOLT-LMM [62] followed by LD score regression [63].

Statistical analysis

We first performed a fixed-effects inverse variance weighted meta-analysis combining the summary statistics data from the UKB and deCODE analyses, followed by a combined analysis of the discovery and replication summary statistics using GWAMA v2.2.2 [64].

ADAMTS6 variants p.Ser90Leu and p.Arg603Trp were created in the Adamts6 cDNA using Q5 Site-Directed Mutagenesis Kit (catalog no. E0554S; New England BioLabs). Primer sequences used for cloning and mutagenesis are available upon request. Each plasmid insert was verified by sequencing. Human embryonic kidney (HEK293) cells obtained from ATCC were maintained in medium supplemented with 10% fetal bovine serum and 100 U/mL penicillin and 100 μg/mL streptomycin. The constructs were transfected with Lipofectamine 3000 Transfection Kit (catalog no. L3000; Invitrogen) following manufacturer’s instructions. After 72 h in serum-free medium, cell lysates were collected in lysis buffer (0.1% NP-40, 0.01% sodium dodecyl sulfate, and 0.05% sodium deoxycholate in phosphate buffered saline [PBS], pH 7.4). Extracts were electrophoresed by reducing SDS-PAGE on 10% Tris-Glycine gels. Proteins were electroblotted to Immobilon-FL membranes (catalog no. IPFL0010, EMD Millipore), incubated with primary antibody anti-myc (Hybridoma core facility; 1:1000; Cleveland Clinic), anti-GAPDH (catalog no. MAB374; 1:5000; EMD Millipore), and anti-Cx43 (catalog no. C6219; 1:2000; Sigma-Aldrich), overnight at 4 °C, followed by IRDye secondary antibodies goat anti-mouse or anti-rabbit (926–68,170, 827–08365; 1:10000; LI-COR) for 1 h at room temperature and visualized by Odyssey CLx (LI-COR). Band intensity was measured using ImageJ (NIH, Bethesda, MD, USA).

Statistics

All values are expressed as mean ± SEM. A paired two-tailed Student’s t-test was used to assess statistical significance.

Recovery and phenotyping of Adamts6 mutant mice

Adamts6 mutant mice were recovered from a recessive ethynitrosourea (ENU) mouse mutagenesis screen conducted using non-invasive in utero fetal echocardiography [40]. Mutants detected with congenital heart defects by ultrasound imaging were recovered either as fetuses or at term and further analyzed by necropsy, followed by histopathology for detailed analysis of intra-cardiac anatomy with three-dimensional reconstructions using episcopic confocal microscopy. From the screen, ten independent Adamts6 mutant lines were recovered, all exhibiting the identical phenotype. Mouse histology, immunostaining and RT-PCR experiments were approved by the Cleveland Clinic Institutional Animal Care and Use Committee (protocol # 2015–1458, IACUC number: 18052990).

Mouse mutation recovery

Mutation recovery was conducted by whole-exome capture using SureSelect Mouse All Exon kit V1, with sequencing carried out using Illumina HiSeq 2000 with minimum 50X
average coverage (BGI Americas). Sequence reads were aligned to the C57BL/6 J mouse reference genome (mm9) and analyzed using CLCBio Genomic Workbench and GATK software. All homozygous mutations were genotyped across all mutants recovered in the mutant line and only the Adamts6 mutation was consistently homozygous across all mutants recovered in the line, the pathogenic identifying it as mutation. Of the ten mutant lines, nine were identified to have the same missense mutation (c.C447G: p.S149R), while one mutant line exhibited loss of the start codon (c.G3A: p.M1) and was confirmed to be null with no Adamts6 transcripts detected with transcript analysis. The Adamts6 missense mutation was subsequently identified as a spontaneous mutation in the C57BL/6 J production colony at the Jackson Laboratory.

Histology and immunofluorescence staining and RNA in situ hybridization
Tissues were fixed in 4% paraformaldehyde in PBS at 4°C overnight followed by paraffin embedding. Sections of 7 μm were used for hematoxylin and eosin staining, picrosirius red staining, and immunofluorescence for Cx43 (catalog no. C6219; 1:800; Sigma-Aldrich) following by secondary goat anti-rabbit antibody (catalog no. 111–035-144; 1:2000; Jackson Immunoresearch Laboratories Inc.). Antigen retrieval, i.e. immersion of slides in citrate-EDTA buffer (10 mM/L citric acid, 2 mM/L EDTA, 0.05% v/v Tween-20, pH 6.2) and microwaving for 1.5 min at 50% power four times in a microwave oven with 30-s intervals intervening was used before immunofluorescence. Immunofluorescence was quantified by the ratio of Cx43 signal to DAPI-positive cell nuclei integrated density (ImageJ; National Institutes of Health, n = 3, with three samples of each myocardium). Adamts6 RNA in situ hybridization was performed using RNAscope (Advanced Cell Diagnostics) following the manufacturer’s protocol. Briefly, 7-μm sections were deparaffinized and hybridized to a mouse Adamts6 probe set (catalog no. 428301; Advanced Cell Diagnostics) using a HybEZ™ oven (Advanced Cell Diagnostics) and the RNAscope 2.5 HD Detection Reagent Kit (catalog no. 322360; Advanced Cell Diagnostics).

Quantitative real-time PCR
Total RNA was isolated using TRIzol (catalog no. 15596018, Invitrogen) and 1 μg of RNA was reverse-transcribed into cDNA with SuperScript III Cells Direct cDNA synthesis system (catalog no. 46–6321, Invitrogen). qPCR was performed with Bullseye EvaGreen qPCR MasterMix (catalog no. BEQPCR-S; MIDSCI) using an Applied Biosystems 7500 instrument. The experiments were performed with three independent samples and confirmed reproducibility. Gapdh was used as a control for mRNA quantity. The ΔΔCt method was used to calculate relative mRNA expression levels of target genes. Primer sequences are as follows: Gapdh: 5′ TGGAGAAAC CTGCAAGTATGA 3′ and 5′ CTGTTGAAG TCGCAAGAGACA 3′; Gja1: 5′ CCTGCTGAG AACCTACATCATC 3′ and 5′GCCCCCTGAAGAAC ACATGAA 3′.

Web resources
Databases
Genotype-Tissue Expression (GTEx) Portal database: http://www.gtexportal.org
Software
seqMeta: http://cran.r-project.org/web/packages/seqMeta/
EasyStrata: https://cran.r-project.org/web/packages/EasyStrata/
PLINK 1.9: https://www.cog-genomics.org/plink
SNPTEST v2.5.4: https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html
GWAMA v2.2.2: https://www.genivarumee.eu/en/tools/gwama

Additional files

- Additional file 1: Table S1. Cohort characteristics. Table S2. Single SNP meta-analyses. Table S3. Sex-stratified analyses. Table S4. SKAT analyses. Table S5. TI-burden analyses. Table S6. ADAMTS6 variant details. Table S7. Cardiac phenotype distribution in Adamts6 mutant mice. (XLSX 475 kb)
- Figure S1. Manhattan plot for European and African-American ancestry single variant analysis. Figure S2. Quantile-quantile plot for European and African-American ancestry single variant analysis. Figure S3. Manhattan plot for EA single variant analysis. Figure S4. QQ plot for EA single variant analysis. Figure S5. Manhattan plot for AA single variant analysis. Figure S6. Quantile-quantile plot for AA single variant analysis. Figure S7. Miami plot European and African-American ancestry sex-stratified single variant analysis. Figure S8. Quantile-quantile plots for European and African-American ancestry sex-stratified single variant analyses. Figure S9. Normal morphology of adult Adamts6 heterozygous hearts. (DOCX 4200 kb)
- Additional file 2: Video S1. (Quicktime) Video to illustrate the DORV phenotype finding in an Adamts6 mutant heart. (MOV 1983 kb)

Funding
This work was funded by a grant to YJ from the British Heart Foundation (PG/12/39/29615).

AGES: This study has been funded by NIH contracts N01-AG-1-2100 and 271201200022C, the NIA Intramural Research Program, Hjartavind (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, VSN: 00

ARIC: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200652526C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. Funding support....
for “Building on GWAS for NHLBI diseases: the U.S. CHARGE consortium” was provided by the NIH through the American Recovery and Reinvestment Act of 2009 (ARRA) (SRC2HL102419).

**BRIGHT:** The Exome Chip genotyping was funded by Wellcome Trust Strategic Awards (883948 and 885473). This work was also supported by the Medical Research Council of Great Britain (Grant no. G05210100); and by the British Heart Foundation (Grant no. PG/02/128). AFD was supported by the British Heart Foundation (Grant nos. RG/07/005/23633 and SP/08/005/25113); and by the European Union Ingenion HyperCare Consortium: Integrated Genomics, Clinical Research, and Care in Hypertension (grant no. LSHM-C4–2006-03709). The BRIGHT study is extremely grateful to all the patients who participated in the study and the BRIGHT nursing team. We would also like to thank the Barts Genome Centre staff for their assistance with this project.

**CHS:** This Cardiovascular Health Study (CHS) research was supported by NHLBI contracts HHSN26820180001C, HHSN268201800036C, HHSN268200800007C, N01HC55222, N01HC58079, N01HC583080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants R01HL69896, U01HL082095, R01HL07652, R01HL105756, R01HL103612, R01HL120993, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org.

The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSA grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Diseases Research (grant DDK083491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**ERF:** The ERF study as a part of EUROSPLAN (European Special Populations Research Networks) was supported by European Community FP6 STRP grant number 018947 (LSHG-C4–2006-01947) and also received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) grant agreement HEALTH-F4–2007-201413 by the European Commission under the programme “Quality of Life and Management of the Living Resources” of 5th Framework Programme (no. QLG2-CT-2002-01254). The ERF study was further supported by ENGAGE consortium and CSMB. High-throughput analysis of the ERF data was supported by joint grant from Netherlands Organisation for Scientific Research and the Russian Foundation for Basic Research (NWO–RFBR 047.017.043). We are grateful to all study participants and their relatives, general practitioners, and neurologists for their contributions to the ERF study and to P Veraart for her help in genealogy, J Vergeer for the supervision of the laboratory work, and P Snijders for his help in data collection.

**FHS:** The Framingham Heart Study (FHS) research reported in this article was supported in part by a grant from the National Heart, Lung, and Blood Institute (NHLBI, HL143093).

**Generation Scotland:** Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). Genotyping of the Generation Scotland and Scottish Family Health Study samples was carried out by the Genetics Core Laboratory at the Clinical Research Facility, Edinburgh, Scotland and was funded by the UK’s Medical Research Council.

**GOCHA:** The Genetics of Cerebral Hemorrhage with Anticoagulation was carried out as a collaborative study supported by grants R01NS073344, R01NS059727, and 3K23NS059774 from the NIH–National Institute of Neurological Disorders and Stroke (NINDS).

**GRAPHIC:** The GRAPHIC Study was funded by the British Heart Foundation (BHF/RG/0000014). NIS and CPN are supported by the British Heart Foundation and is a NIHR Senior Investigator. This work falls under the portfolio of research supported by the NIHR Leicester Cardiovascular Biomedical Research.

**INGF-FVG:** This study has been funded by Regione FVG (L.26/2008).

**INTER99:** The Inter99 was initiated by Torben Jørgensen (PI), Knut Borch-Johnsen (co-PI), Hans Ibsen and Troels F. Thomsen. The steering committee comprises the former two and Charlotte Pisinger. The study was financially supported by grants from the Danish Centre for Health Technology Assessment, Novo Nordisk Inc., Research Foundation of Copenhagen County, Ministry of Internal Affairs and Health, the Danish Heart Foundation, the Danish Pharmaceutical Association, the Augustinus Foundation, the Ib Henriksen Foundation, the Becket Foundation, and the Danish Diabetes Association. The Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk).

**JHS:** We thank the Jackson Heart Study (JHS) participants and staff for their contributions to this work. The JHS is supported by contracts HHSN266201300004C, HHSN26820130004C, HHSN26820130004C, HHSN26820130004C, HHSN268201300004C, and NHLBI grants HL101575, R01HL103612, R01HL120993, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal JHS investigators and institutions can be found at CHS-NHLBI.org.

**KORA:** The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ.

**Korcula:** This work was funded by the Medical Research Council UK, The Croatian Ministry of Science, Education and Sports (grant 216–100831–0302), the Croatian Science Foundation (grant 8873), the Centre of Excellence in Personalized health care, and the Centre of Competencies for Integrative Treatment, Prevention and Rehabilitation using TMS.

**LifeLines:** The LifeLines Cohort Study and generation and management of GWAS genotype data for the LifeLines Cohort Study are supported by The Netherlands Organization of Scientific Research NWO (grant 175.010.007.008), the Economic Structure Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), the Province of Groningen, University Medical Center Groningen, the University of Groningen, Dutch Kidney Foundation, and Dutch Diabetes Research Foundation, Niek Verweij is supported by NWO-VENI (016.186.125) and Marie Skłodowska-Curie CF (call: H2020-MSCA-IF-2014, Project ID: 661395).

**LUHP:** Folkert W. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre. Ilonca Vaartjes is supported by a Dutch Heart Foundation grant DHF project “Facts and Figures.”

**MGH-CAMP:** Dr. Patrick Ellinor is funded by NIH grants (R201HL092577, R01HL129814, R01HL104156, and K24HL105780) and American Heart Association Established Investigator Award 13EA14220013 (Ellinor). Dr. Steve Lubitz is funded by NIH grants K23HL141724 and a Doris Duke Charitable Foundation Clinical Scientist Development Award 2014105.

**NEO:** The authors of the NEO study thank all individuals who participated in the Netherlands Epidemiology in Obesity study, all participating general practitioners for inviting eligible participants, and all research nurses for collection of the data. We thank the NEO study group, Pat van Beelen, Petra Noordijk, and Ingeborg de Jonge for the coordination, lab, and data management of the NEO study. We also thank Aine Maan for the analyses of the electrocardiograms. The genotyping in the NEO study was supported by the Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative Medicine. Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023).

**RS-I:** The generation and management of the Illumina Exome Chip v1.0 array data for the Rotterdam Study (RS-I) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The Exome chip array dataset was funded by the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, from the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO)-sponsored Netherlands Consortium for Healthy Aging (NCHA; project nr. 050–060–810); the Netherlands Organization for Scientific Research (NWO; project number 184021007); and by the Rainbow Project (RP10; Netherlands Exome Chip Project) of the Biobanking and Biomolecular Research Infrastructure Netherlands (BBMRI-NL; www.bbmri.nl). We thank Ms. Mila Jhamai, Ms. Sarah Higgins, and Dr. Marij Verkerk for their help in creating the exome chip database, and Carolina Medina-Gomez, MSc, Lennard Karsten, MSc, and Linda Broer PhD for QC and variant calling. Variants were called using the best practice protocol developed by Grove et al. as part of the CHARGE consortium exome chip central calling effort. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization
for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists. The work of Bruno H. Stricker is supported by grants from the Netherlands Organization for Health Research and Development (ZonMw) (Priority Medicines Elderly 113102005 to ME and DoolmatheidsOnderzoek 80–82500–98–10208 to BHS). The work of Mark Eijgelsheim is supported by grants from the Netherlands Organization for Health Research and Development (ZonMw) (Priority Medicines Elderly 113102005 to ME and DoolmatheidsOnderzoek 80–82500–98–10208 to BHS).

SHIP: SHIP is supported by the MBMF (grants 01ZZ0603, 01ZZ0103, and 01ZZ0403) and the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG]; grant GR 1912/5–1). SHIP and SHIP-TREND are part of the Community Medicine Research net (CMR) of the Ernst-Moritz-Arndt University Greifswald (EMAU) which is funded by the MBMF as well as the Ministry for Education, Science and Culture and the Ministry of Labor, Equal Opportunities, and Social Affairs of the Federal State of Mecklenburg-West Pomerania. The CMR encompasses several research projects that share data from SHIP. The EMAU is a member of the Center of Knowledge Interchange (CKI) program of the Siemens AG. SNP typing of SHIP and SHIP-TREND using the Illumina Infinium HumanExome BeadChip (version v1.0) was supported by the MBMF (grant 03Z1CN22). We thank all SHIP and SHIP-TREND participants and staff members as well as the genotyping staff involved in the generation of the SNP data.

TWINsUK: TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London.

UKBB: This research has been conducted using the UK Biobank Resource (application 8256 - Understanding genetic influences in the response of the cardiac electrical system to exercise) and is supported by Medical Research Council grant MR/N025083/1. We also acknowledge the support of the NIHR Cardiovascular Biomedical Research Unit at Barts and Queen Mary University of London, UK. PD Lambiase acknowledges support from the UCLH Biomedicine NIHR, MO is supported by an IEF 2013 Marie Curie fellowship. JR acknowledges support from the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007–2013) under REA grant agreement no. 608765.

YFS: The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134509 (Eeye), 126925, 121584, 124282, 129578 (Salve), 177787 (Eendi), and 41071 (Skidi); the Social Insurance Institution of Finland, Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku Universities Hospital (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; and Diabetes Research Foundation of Finnish Diabetes Association. The expert technical assistance in the statistical analyses by Irina Lisinen is gratefully acknowledged.

Cell culture and biochemistry: Funding was provided by the National Institutes of Health (Program of Excellence in Glycoscience award HL107147 to SSA and F32AR063548 to TJM) and the David and Lindsay Morgenthaler Postdoctoral Fellowship (to TJM) and by the Allen Distinguished Investigator Program, through support made by The Paul G. Allen Frontiers Group and the American Heart Association (to SSA).

Mutant mouse model: Adams86 mutant mice were generated and further propagated and analyzed by funding provided by NIH grants HL098180 and HL132024 (to CWL) and by the Allen Distinguished Investigator Program, through support made by The Paul G. Allen Frontiers Group and the American Heart Association (to SSA).

Availability of data and materials

Authors’ contributions

Ethics approval and consent to participate
All participating studies received approval by their respective local institutional review boards and ensured that written informed consent was obtained from all study participants, following the recommendations of the Declaration of Helsinki.

Exome discovery and replication analyses
AGES: The study is approved by the Icelandic National Bioethics Committee, (VSN: 00–063) and the Data Protection Authority. ARIC: Institutional Review Board approvals were obtained by each participating ARIC study center (the Universities of NC, MS, MN, and John Hopkins University) and the coordinating center (University of NC); the research was conducted in accordance with the principles described in the Helsinki Declaration. All participants in the ARIC study gave informed consent. For more information see dbGaP Study Accession: phs000287.v2.p1. JSHP: IRB number H.34.99.07.02.A1. Manuscript proposal number M52572.

BRIGHT: All individuals in the BRIGHT study participated as volunteers and were recruited via hypertension registers from the MRC General Practice Framework in the UK. Ethics Committee approval was obtained from the multi-and local research committees of the partner institutes, and all participants gave written informed consent.

CHS: CHS was approved by institutional review committees at each site, the participants gave informed consent, and those included in the present analysis consented to the use of their genetic information for the study of cardiovascular disease. It is the position of the UW IRB that these studies of de-identified data, with no patient contact, do not constitute human subjects research. Therefore, we have neither an approval number, nor an exemption.

deCODE: The deCODE Electrocardiogram (ECC) study was approved by the Data Protection Commission of Iceland and the National Bioethics Committee of Iceland [VSN2015.0302/03.01]. Written informed consent was obtained from individuals donating samples. Personal identifiers associated with medical information and samples were encrypted with a third-party encryption system as provided by the Data Protection Commission of Iceland.

ERF: The Medical Ethics Committee of the Erasmus University Medical Center approved the ERF study protocol and all participants, or their legal representatives, provided written informed consent.

FHS: The Boston University Medical Campus Institutional Review Board approved the FHS genome-wide genotyping (protocol number H-226671).

Generation Scotland: Data were collected for GG5FHS during 2006–2011 with ethical approval from the NHS Tayside Committee on Medical Research Ethics A (ref 05/S1401/89). All participants gave written informed consent.

Page 13 of 17

Fibrillation.

Broad Institute focused on the genetics and therapeutics of atrial fibrillation. MGH-CAMP: Dr. Ellinor is the PI on a grant from Bayer HealthCare to the Committee. Inter99: Written informed consent was obtained from all participants and the study was approved by the Scientific Ethics Committee of the Capital Region of Denmark (KA98155, H-3-2012-155) and was in accordance with the principles of the Declaration of Helsinki II.

KORA: Written informed consent was obtained from all participants and the study was approved by the local ethics committee (Bayernische Landesärztekammer).

Korcula: Ethical approval was given for recruitment of all Korcula study participants by ethics committees in both Scotland and Croatia. All volunteers gave informed consent before participation.

Lifelines: The Lifelines study followed the recommendations of the Declaration of Helsinki and was in accordance with research code of the University Medical Center Groningen (UMCG). The Lifelines study is approved by the medical ethical committee of the UMCG, the Netherlands. All participants signed an informed consent form before they received an invitation for the physical examination. For a comprehensive overview of the data collection, please visit the LifeLines catalog at https://catalogue.lifelines.nl/menu/main/protocolviewer.

MGH CAMP: The Institutional Review Board at MGH reviews the study protocol annually. Each participant provided written, informed consent before enrolment.

NEO: The Netherlands Epidemiology of obesity (NEO) study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative Medicine. All participants gave written informed consent and the Medical Ethical Committee of the Leiden University Medical Center (LUMC) approved the study design.

RS: The Rotterdam Study has been approved by the medical ethics committee according to the Population Study Act Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the Netherlands. Written informed consent was obtained from all participants.

SHIP: The SHIP study followed the recommendations of the Declaration of Helsinki. The study protocol of SHIP was approved by the medical ethics committee of the University of Greifswald. Written informed consent was obtained from each of the study participants. The SHIP study is described in PMID: 20167617.

TwinUK: The study has ethical approval from the NRES Committee London–Westminster, London, UK (EC04/015). Written consent was obtained from all participants. Research was carried out in accordance with the Helsinki declaration.

UKBB: The UK study has approval from the North West Multi-Centre Research Ethics Committee and all participants provided informed consent.

UHP: The Utrecht Health Project has been approved by the Medical Ethics Committee of the University Medical Centre Utrecht. All participants gave written informed consent. The masking of all personal data for researchers and for other possible users of UHP has been regulated in a legal document.

WHI: All WHI participants provided written and informed consent. All study sites received approval to conduct this research from local Institutional Review Boards at the Fred Hutchinson Cancer research Center.

YFS: The Young Finns Study was approved by the local ethics committees (University Hospitals of Helsinki, Turku, Tampere, Kuopio, and Oulu) and was conducted following the guidelines of the Declaration of Helsinki. All participants gave their written informed consent.

In vivo mouse work

Cleveland Clinic Lerner Research Institute: All mouse experiments were approved by the Cleveland Clinic Institutional Animal Care and Use Committee (protocol no. 2015–1458, IACUC number: 18052990), and by the University of Pittsburgh Institutional Animal Care and Use Committee.

Competing interests

MGH-CAMP: Dr. Ellinor is the PI on a grant from Bayer HealthCare to the Broad Institute focused on the genetics and therapeutics of atrial fibrillation.

CHS: Dr. Bruce Psaty serves on the DSMB of a clinical trial funded by the manufacturer (Zoll LifeCor) and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson.


Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Genetics Research Centre, Molecular and Clinical Sciences Institute, St George's University of London, London SW17 0RE, UK. 2Department of Public Health and Primary Care, MRC/BHF Cardiovascular Epidemiology Unit, University of Cambridge, Strangeways Research Laboratory, Worts' Causeway, Cambridge CB1 8RN, UK. 3Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44109, USA. 4Department of Medicine, Cardiovascular Health Research Unit, University of Washington, Seattle, WA 98101, USA. 5deCODE genetics/Amgen, Inc., 101 Reykjavik, Iceland. 6Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK. 7NHRI Barts Cardiovascular Biomedical Research Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK. 8Predoctoral Training Program in Human Genetics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 9Department of Medical Informatics Erasmus MC - University Medical Center, P.O. Box 2040, Rotterdam 3000 CA, The Netherlands. 10The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark. 11Institute for Maternal and Child Health - ICREC “Burlo Garofolo”, 34157 Trieste, Italy. 12Institute of Cardiovascular Science, University College London, London WC1E 6BT, UK. 13Department of Developmental Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15201, USA. 14Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 15Department of Cardiovascular Sciences, University of Leicester, Cardiovascular Research Centre, Glenfield Hospital, Leicester LE3 9QP, UK. 16Leicest NIHR Biomedical Research Centre, Glenfield Hospital, Leicester LE3 9QP, UK. 17Cardiovascular Department, Ospedali Riuniti and University of Trieste, 34100 Trieste, Italy. 18CABIM School for Cardiovascular Diseases, Maastricht Center for Systems Biology (MaCBS), and Department of Biochemistry, Maastricht University, Universiteitssingel 60, Maastricht 6229 ER, The Netherlands. 19Department of Epidemiology, Genetic Epidemiology Unit, Erasmus University Medical Centre, Rotterdam, The Netherlands. 20Department of Clinical Epidemiology, Leiden University Medical Center, Leiden 2300RC, The Netherlands. 21Department of Medicine, Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA 02118, USA. 22Biostatistics Department, Boston University School of Public Health, Boston, MA 02118, USA. 23Department of Clinical Chemistry, Fimlab Laboratories, 35320 Tampere, Finland. 24Department of Clinical Chemistry, Faculty of Medicine and Life Sciences, University of Tampere, 33014 Tampere, Finland. 25Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK. 26Department of Data Science, School of Population Health, University of Mississippi Medical Center, Jackson, MS 343216, USA. 27Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany. 28Department of Medicine I, University Hospital Munich, Ludwig-Maximilians University, Munich, Germany. 29German Centre for Cardiovascular Research (DZHK); partner site: Munich Heart Alliance, Munich, Germany. 30Mechanical Engineering Department, University College London, London WC1E 6BT, UK. 31Barts Heart Centre, St Bartholomews Hospital, London EC1A 7BE, UK. 32Institute of Cardiovascular and Medical Sciences, University of Glasgow, BHF GCR, Glasgow G12 8TA, UK. 33Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA. 34Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. 35Division Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands. 36Icelandic Heart Association, 201 Kopavogur, Iceland. 37Department of Cardiology, Faculty of Medicine,
References


Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions